Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2020 16:03 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

EMERYVILLE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May...
April 10, 2020 16:06 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., April 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven...
March 06, 2020 16:39 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new...
February 25, 2020 16:03 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Fourth Quarter and Full Year 2019 Financial Results

- Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018;total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI® product sales of $16.3...
February 20, 2020 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at Upcoming Healthcare Conferences

EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
February 19, 2020 16:02 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,...
February 13, 2020 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
February 11, 2020 16:15 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

- Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease - Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF...
January 10, 2020 16:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new...
January 08, 2020 09:15 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020

-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth...